



7th August 2025

SomnoMed FY25 Results Webinar and Investor Presentation

SomnoMed Limited (SomnoMed or the Company) (ASX: SOM) advises its FY25 Financial Results and Investor Presentation will be released to the ASX pre-market open on Thursday 28th August 2025.

Karen Borg and Amrita Blickstead, Co-CEOs, and Ye-Fei Guo, CFO, will host an investor presentation and Q&A on the FY25 Results via a webinar commencing at 11am AEST on Thursday 28 August 2025.

Participants are invited to register for the webinar via the following link:

https://us06web.zoom.us/webinar/register/WN_3q78RWgYRRWnQhJx6By36w

Once you have registered you will receive an email confirming your attendance and information about joining the webinar.

Alternatively, participants may dial into the webcast for audio only:

Australian dial in numbers:

+61 8 7150 1149 or
+61 2 8015 6011 or
+61 3 7018 2005 or
+61 7 3185 3730 or
+61 8 6119 3900

Dial in numbers for other countries:

https://us06web.zoom.us/join/zoomconference?m=ODEwMDY0MTg1NjE.HcvOA50qRRbE0XKsbIY5VPcd_uRod2tY

Meeting ID: 810 0641 8561

Passcode: 026804

Authorised by the Company Secretary of SomnoMed Limited

About SomnoMed SomnoMed is a public company providing treatment solutions for sleep-related breathing disorders including obstructive sleep apnea, snoring and bruxism. SomnoMed was commercialised on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent[®] becoming the state-of-the-art and clinically proven medical oral appliance therapy for more than 1 million patients in over 20 countries. For additional information, visit SomnoMed at <http://www.somnomed.com.au>

Investor Enquiries

Investor Relations

ir@somnomed.com